Dovato demonstrated non-inferior efficacy compared to TAF-based regimens in virologically suppressed adults with HIV-1 in Phase III study.
List view / Grid view
HIV (Human Immunodeficiency Virus)
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
The investigational vaccine tested in sub-Saharan Africa posed no safety concerns but did not provide sufficient HIV protection.
Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
Collaborating with global partners BioNTech will work to develop a safe and effective malaria vaccine and set up its sustainable supply for the African continent.
To promote the safe and ethical use of genome editing for the treatment of disease and genetic disorders WHO has published the first global recommendations.
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
The first-in-human study will evaluate the safety and efficacy AGT103-T, a cell and gene therapy product for HIV, in up to six participants.
In this article, learn from GlaxoSmithKline’s and ViiV Healthcare’s team as they discuss the key elements that enabled them to build and set up a dedicated manufacturing facility for Rukobia in only 15 months.
EPR’s Hannah Balfour discusses the findings of market research reports, unveiling how, where and why the global clinical trial packaging market will grow between now and 2027.
The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.
The highest doses of the novel maturation inhibitor, GSK3640254, had the greatest antiviral activity and were shown to be safe in 34 treatment-naïve adults with HIV.